
| Species: | Mouse |
| Applications: | WB IHC ELISA FC |
| Immunogen Range: | A purified recombinant fragment of human ApoE expressed in E. Coli |
| Clonality: | Monoclonal Antibody |
| Isotype: | IgG1 |
| GENE ID: | 348 |
| Swiss Prot: | P02649 |
| Synonyms: | AD2, LPG, LDLCQ5, MGC1571 |
| Purification: | Affinity chromatography |
| Storage: | Store at -20°C or -80°C in PBS with 0.02% sodium azide and 50% glycerol. Avoid freeze/thaw cycles. |
| Background: | Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E, a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells. ApoE is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. The APOE gene is mapped to chromosome 19 in a cluster with APOC1 and APOC2. Defects in apolipoprotein E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. Tissue specificity: Occurs in all lipoprotein fractions in plasma. It constitutes 10-20% of very low density lipoproteins (VLDL) and 1-2% of high density lipoproteins (HDL). APOE is produced in most organs. Significant quantities are produced in liver, brain, spleen, lung, adrenal, ovary, kidney and muscle. |
| Caculated MW: | 36 kDa |
| Observed MW: | Refer to Figures |
| Applications: |
WB 1:500-1:2000 IHC 1:200-1:1000 FC 1:200-1:400 |
| Reacitivity: | Human |